Form 13-F position report

EDGEWISE THERAPEUTICS INC

Reported by DEERFIELD MANAGEMENT COMPANY L P SERIES C

EWTX CUSIP 28036F105 Manager CIK 0001009258

Reported 2,874,586 shares, unchanged from the prior quarter.

Reported value -1.3%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 0.86% This manager · Q2 2024
Shares 2,874,586 Quarter-end amount reported
Reported value $51,771,294 Fair value at quarter end
Consecutive quarters held 14 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 60098000
2022-03-31 38151000
2022-06-30 31308000
2022-09-30 38702000
2022-12-31 35162245
2023-03-31 26234024
2023-06-30 30481812
2023-09-30 22536875
2023-12-31 43028519
2024-03-31 52432449
2024-06-30 51771294
2024-09-30 47535050
2024-12-31 55496190
2025-03-31 45727198
2025-06-30 27102565
2025-09-30 12419557
2025-12-31 19000697
2026-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarterly reported position history for EDGEWISE THERAPEUTICS INC held by DEERFIELD MANAGEMENT COMPANY L P SERIES C.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2026 Reduced 0 -765,694 (-100.0%) 0 $0 2026-05-15
Q4 2025 Unchanged 765,694 0 (0.0%) 0.24% $19,000,697 2026-02-17
Q3 2025 Reduced 765,694 -1,301,626 (-63.0%) 0.19% $12,419,557 2025-11-14
Q2 2025 Reduced 2,067,320 -11,189 (-0.5%) 0.49% $27,102,565 2025-08-14
Q1 2025 Unchanged 2,078,509 0 (0.0%) 0.9% $45,727,198 2025-05-15
Q4 2024 Added 2,078,509 +297,503 (16.7%) 1.05% $55,496,190 2025-02-14
Q3 2024 Reduced 1,781,006 -1,093,580 (-38.0%) 0.71% $47,535,050 2024-11-14
Q2 2024 Unchanged 2,874,586 0 (0.0%) 0.86% $51,771,294 2024-08-14
Q1 2024 Reduced 2,874,586 -1,058,551 (-26.9%) 0.91% $52,432,449 2024-05-15
Q4 2023 Unchanged 3,933,137 0 (0.0%) 0.79% $43,028,519 2024-02-14
Q3 2023 Unchanged 3,933,137 0 (0.0%) 0.5% $22,536,875 2023-11-14
Q2 2023 Unchanged 3,933,137 0 (0.0%) 0.65% $30,481,812 2023-08-14
Q1 2023 Unchanged 3,933,137 0 (0.0%) 0.58% $26,234,024 2023-05-15
Q4 2022 Unchanged 3,933,137 0 (0.0%) 0.73% $35,162,245 2023-02-14
Q3 2022 Unchanged 3,933,137 0 (0.0%) 0.77% $38,702,000 2022-11-14
Q2 2022 Unchanged 3,933,137 0 (0.0%) 0.65% $31,308,000 2022-08-15
Q1 2022 Unchanged 3,933,137 0 (0.0%) 0.85% $38,151,000 2022-05-16
Q4 2021 Unchanged 3,933,137 0 (0.0%) 1.26% $60,098,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

162 managers reported EDGEWISE THERAPEUTICS INC for Q2 2024.

Managers reporting EDGEWISE THERAPEUTICS INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ORBIMED ADVISORS LLC Unchanged 15,021,721 0 5.38% $270,541,195 14 qtrs
RA CAPITAL MANAGEMENT L P Unchanged 8,909,091 0 2.12% $160,452,729 2 qtrs
Novo Holdings A S New 6,344,430 +6,344,430 6.16% $114,263,184 14 qtrs
BlackRock Inc Added 6,015,711 +848,705 < 0.01% $108,342,955 14 qtrs
BAKER BROS ADVISORS LP Unchanged 5,840,059 0 1.34% $105,179,463 14 qtrs
FMR LLC Reduced 4,780,563 -1,585,161 < 0.01% $86,097,933 14 qtrs
VANGUARD GROUP INC Added 4,508,166 +490,733 < 0.01% $81,192,069 14 qtrs
Frazier Life Sciences Management L P Added 3,731,067 +427,500 3.14% $67,196,517 6 qtrs
Cormorant Asset Management LP Unchanged 3,006,534 0 3.13% $54,147,677 14 qtrs
DEERFIELD MANAGEMENT COMPANY L P SERIES C This report Unchanged 2,874,586 0 0.86% $51,771,294 14 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
2,874,586
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.